Pouyan A, Ghorbanlo M, Eslami M, Jahanshahi M, Ziaei E, Salami A
Mol Cancer. 2025; 24(1):58.
PMID: 40011944
PMC: 11863469.
DOI: 10.1186/s12943-025-02267-0.
Geyer L, Wolf T, Chenard M, Cebula H, Schott R, Noel G
Cancers (Basel). 2023; 15(5).
PMID: 36900302
PMC: 10000516.
DOI: 10.3390/cancers15051512.
Luo J, Junaid M, Hamid N, Duan J, Yang X, Pei D
Int J Med Sci. 2022; 19(14):2071-2079.
PMID: 36483593
PMC: 9724244.
DOI: 10.7150/ijms.77287.
Jaiswal M, Tripathi A, Singh D, Kumar A, Singh M, Batra N
Cureus. 2022; 14(2):e22346.
PMID: 35223330
PMC: 8857909.
DOI: 10.7759/cureus.22346.
Wang Y, Zhang S, Sun Q, Yuan F, Zhao L, Ye Z
Med Oncol. 2021; 38(11):132.
PMID: 34581882
DOI: 10.1007/s12032-021-01580-0.
Anticancer Mechanism of Curcumin on Human Glioblastoma.
Wong S, Kamarudin M, Naidu R
Nutrients. 2021; 13(3).
PMID: 33809462
PMC: 7998496.
DOI: 10.3390/nu13030950.
Autophagy as a Potential Therapy for Malignant Glioma.
Escamilla-Ramirez A, Castillo-Rodriguez R, Zavala-Vega S, Jimenez-Farfan D, Anaya-Rubio I, Briseno E
Pharmaceuticals (Basel). 2020; 13(7).
PMID: 32707662
PMC: 7407942.
DOI: 10.3390/ph13070156.
Pediatric low-grade glioma in the era of molecular diagnostics.
Ryall S, Tabori U, Hawkins C
Acta Neuropathol Commun. 2020; 8(1):30.
PMID: 32164789
PMC: 7066826.
DOI: 10.1186/s40478-020-00902-z.
The Coincidence Between Increasing Age, Immunosuppression, and the Incidence of Patients With Glioblastoma.
Ladomersky E, Scholtens D, Kocherginsky M, Hibler E, Bartom E, Otto-Meyer S
Front Pharmacol. 2019; 10:200.
PMID: 30971917
PMC: 6446059.
DOI: 10.3389/fphar.2019.00200.
Microfluidics in Malignant Glioma Research and Precision Medicine.
Logun M, Zhao W, Mao L, Karumbaiah L
Adv Biosyst. 2018; 2(5).
PMID: 29780878
PMC: 5959050.
DOI: 10.1002/adbi.201700221.
The Role of and Gene Polymorphisms in Prolactinoma: Gene Polymorphisms May Be Associated with Tumor Shrinkage.
Turgut S, Ilhan M, Turan S, Karaman O, Yaylim I, Kucukhuseyin O
In Vivo. 2017; 31(3):357-363.
PMID: 28438863
PMC: 5461445.
DOI: 10.21873/invivo.11067.
Rapid progression to glioblastoma in a subset of IDH-mutated astrocytomas: a genome-wide analysis.
Richardson T, Snuderl M, Serrano J, Karajannis M, Heguy A, Oliver D
J Neurooncol. 2017; 133(1):183-192.
PMID: 28421459
DOI: 10.1007/s11060-017-2431-y.
Association between p16(CDKN2A) C540G polymorphism and tumor behavior in prolactinoma: A single-center study.
Cander S, Karkucak M, Gul O, Sag S, Yakut T, Ersoy C
Biomed Rep. 2014; 2(4):589-595.
PMID: 24944814
PMC: 4051468.
DOI: 10.3892/br.2014.281.
Aberrant signaling pathways in glioma.
Nakada M, Kita D, Watanabe T, Hayashi Y, Teng L, Pyko I
Cancers (Basel). 2013; 3(3):3242-78.
PMID: 24212955
PMC: 3759196.
DOI: 10.3390/cancers3033242.
CDKN2A exon-wise deletion status and novel somatic mutations in Indian glioma patients.
Sibin M, Bhat D, Lavanya C, Manoj M, Aakershita S, Chetan G
Tumour Biol. 2013; 35(2):1467-72.
PMID: 24065197
DOI: 10.1007/s13277-013-1201-5.
Something old and something new about molecular diagnostics in gliomas.
Horbinski C
Surg Pathol Clin. 2013; 5(4):919-939.
PMID: 23459421
PMC: 3583362.
DOI: 10.1016/j.path.2012.09.001.
A complete compilation of matrix metalloproteinase expression in human malignant gliomas.
Hagemann C, Anacker J, Ernestus R, Vince G
World J Clin Oncol. 2012; 3(5):67-79.
PMID: 22582165
PMC: 3349915.
DOI: 10.5306/wjco.v3.i5.67.
Paradoxical relationship between the degree of EGFR amplification and outcome in glioblastomas.
Hobbs J, Nikiforova M, Fardo D, Bortoluzzi S, Cieply K, Hamilton R
Am J Surg Pathol. 2012; 36(8):1186-93.
PMID: 22472960
PMC: 3393818.
DOI: 10.1097/PAS.0b013e3182518e12.
A mathematical methodology for determining the temporal order of pathway alterations arising during gliomagenesis.
Cheng Y, Beroukhim R, Levine R, Mellinghoff I, Holland E, Michor F
PLoS Comput Biol. 2012; 8(1):e1002337.
PMID: 22241976
PMC: 3252265.
DOI: 10.1371/journal.pcbi.1002337.
Clinical stratification of glioblastoma based on alterations in retinoblastoma tumor suppressor protein (RB1) and association with the proneural subtype.
Goldhoff P, Clarke J, Smirnov I, Berger M, Prados M, James C
J Neuropathol Exp Neurol. 2011; 71(1):83-9.
PMID: 22157621
PMC: 3246124.
DOI: 10.1097/NEN.0b013e31823fe8f1.